AXQ Capital’s SpringWorks Therapeutics SWTX Stock Holding History

AXQ Capital’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,214	Closed	-$396K	–	635
2022 Q4	$396K	Buy	+15,214	New	+$375K	0.28%	136

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

AXQ Capital's SWTX Position: Q1 2023 in Review

AXQ Capital sold out of SpringWorks Therapeutics (SWTX) in Q1 2023, closing a stake of 15,214 shares — an estimated $396K sold.

AXQ Capital first reported a position in SWTX in Q4 2022 and held it in 1 quarter. The position peaked at $396K in Q4 2022. 148 funds tracked by Wall St. Rank hold SWTX as of Q1 2023.

AXQ Capital reported no remaining SpringWorks Therapeutics position as of Q1 2023 after selling out during the quarter.
AXQ Capital sold 15,214 SpringWorks Therapeutics shares in Q1 2023, an estimated $396K.
AXQ Capital first reported a position in SpringWorks Therapeutics in Q4 2022 and held it in 1 quarter.
AXQ Capital's SpringWorks Therapeutics position peaked at $396K in Q4 2022.
148 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q1 2023.

Based on AXQ Capital's 13F filing for Q1 2023, filed 10 May 2023.